Acadian Asset Management’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAC
VCM
6CM
EAM
Acadian Asset Management's RNAC Position: Q1 2026 in Review
Acadian Asset Management opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 23,484 shares worth $142K. The stake represents ﹤0.01% of the portfolio and ranks #1673 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in RNAC as recently as Q3 2024.
Acadian Asset Management first reported a position in RNAC in Q2 2019 and has held it in 13 quarters since. The position peaked at $3.4M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Acadian Asset Management held 23,484 shares of Cartesian Therapeutics worth $142K as of Q1 2026.
- Cartesian Therapeutics was a new Acadian Asset Management position in Q1 2026.
- Cartesian Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1673 holding.
- Acadian Asset Management first reported a position in Cartesian Therapeutics in Q2 2019 and has held it in 13 quarters since.
- Acadian Asset Management's Cartesian Therapeutics position peaked at $3.4M in Q3 2021.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.